Picture BIO Deutschland Biotech Investors Day BID 2019 Würzburg 600x60px
Organisation › Details

Inflection Biosciences Ltd.

Inflection Biosciences Ltd, based in Dublin and London, is developing small molecule therapeutics for the treatment of cancer. The Company's pipeline of highly innovative cancer treatments were licensed from the Spanish National Cancer Research Centre (CNIO). The pipeline comprises IBL-202 (PIM/PI3K inhibitor) and IBL-301 (PIM/PI3K/mTOR inhibitor), selected from a series of unique dual mechanism kinase inhibitors and the IBL-100 series (highly selective pan-PIM kinase inhibitors), currently in pre-clinical stages of development. Data generated to date suggests potential application in a range of haematological malignancies and treatment resistant solid tumours. Inflection Biosciences was named ‘Start-up Company of the Year’ at the 2014 Irish Pharma Awards. *


Period Start 2013-07-27 existent
Products Industry small-molecule cancer drug
  Industry 2 drug development
Person Person Cunningham, Darren (Inflection Biosciences 201306 CEO)
Region Region Dublin
  Country Ireland, Republic of
  Street Carysfort Avenue
  City n. a. Blackrock, Co. Dublin
  Tel +353-1-4003615
    Address record changed: 2013-09-28
Basic data Employees n. a.
    * Document for �About Section�: Inflection Biosciences Ltd.. (3/9/15). "Press Release: Inflection Biosciences Raises €725,000 in Second Financing Round". Dublin.
Record changed: 2018-04-16


Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px

More documents for Inflection Biosciences Ltd.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture BIO Deutschland Biotech Investors Day BID 2019 Würzburg 600x60px

» top